Announcements
- ProQR Announces First Quarter 2024 Operating and Financial Results
- ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
- ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
- ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
- ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
- ProQR Announces Year End 2023 Operating and Financial Results
- ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
- ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
- ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
- ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
More ▼
Key statistics
As of last trade, ProQR Therapeutics NV (0PQ:DEU) traded at 1.61, 55.16% above the 52 week low of 1.04 set on Nov 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.68 |
---|---|
High | 1.77 |
Low | 1.61 |
Bid | 1.64 |
Offer | 1.75 |
Previous close | 1.68 |
Average volume | 459.20 |
---|---|
Shares outstanding | 81.35m |
Free float | 63.11m |
P/E (TTM) | -- |
Market cap | 149.69m USD |
EPS (TTM) | -0.3589 USD |
Data delayed at least 15 minutes, as of May 28 2024.
More ▼